Search for Clinical Trial Results
Leukemia, Myeloid, Chronic-Phase - 25 Studies Found
Status | Study |
Withdrawn |
Study Name: Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms Condition: Leukemia, Myeloid, Chronic-Phase Date: 2012-07-24 |
Terminated |
Study Name: Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Condition: Leukemia, Myeloid, Chronic Phase Date: 2005-07-27 Interventions: Drug: Imatinib mesylate Imatinib is packaged in bottles as 100mg and 400mg tablets |
Completed |
Study Name: Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey Condition: Leukemia, Myeloid, Chronic-Phase (CML-CP) Date: 2010-08-24 Interventions: Drug: Imatinib Drug being observed but not provided |
Active, not recruiting |
Study Name: Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy Condition: Chronic Phase CML Date: 2011-10-14 Interventions:
|
Active, not recruiting |
Study Name: Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib Condition: Chronic Phase Chronic Myeloid Leukemia Date: 2012-05-04 Interventions:
|
Not yet recruiting |
Study Name: A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML Condition: Leukemia, Chronic Myeloid Date: 2016-11-22 Interventions:
|
Active, not recruiting |
Study Name: A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib Condition: Leukemia Date: 2008-10-21 Interventions: Drug: Dasatinib Other Name: Sprycel (BMS-354825) |
Active, not recruiting |
Study Name: Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients Condition: Chronic Phase Chronic Myeloid Leukemia Date: 2012-10-03 Interventions:
|
Active, not recruiting |
Study Name: Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) Condition: Leukemia, Myelogenous, Chronic Date: 2005-08-11 Interventions: Drug: Nilotinib 400 mg orally twice daily Other Name |
Terminated |
Study Name: Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib Condition: Leukemia, Myeloid, Chronic Date: 2006-05-01 Interventions:
|